Skip to Main Content

Paper Details

Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group.
J Clin Oncol
12
2022
ANBL0032, Allergic reactions, Children, FCGR3A, FCGR3A genotype, GD2, Human, International, Neuroblastoma, Patients, antichimeric antibody, autologous stem cell, capillary leak, dinutuximab, fever, granulocyte-macrophage colony-stimulating factor, hypotension, interleukin-2, neuroblastoma, patients, tumor
Author NameAffiliation
Malcolm A SmithClinical Investigations Branch, National Cancer Institute
Malcolm A SmithClinical Investigations Branch, National Cancer Institute
Susan L CohnUniversity of Chicago
John M MarisChildren's Hospital of Philadelphia and the University of Pennsylvania
John M MarisChildren's Hospital of Philadelphia and the University of Pennsylvania
Rochelle BagatellChildren's Hospital of Philadelphia and the University of Pennsylvania
  • 1 - 6

Datasets

Release 1.2